Table 2 Natural product of the epigenetic target and clinical trials
From: Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy
Natural product | Epigenetic target | Condition | References | Clinical trial (Condition) |
|---|---|---|---|---|
Resveratrol | DNMT | Breast cancer | 95 | NCT00256334 (Colon Cancer) NCT00433576 (Colon Cancer) |
Curcumin | DNMT EZH2 | Prostate cancer Lung cancer | 96–99 | NCT03211104 (Prostate cancer) NCT01333917 (Colon Cancer) NCT02439385 (Colon Cancer) NCT01160302 (Head and Neck Cancer) NCT01042938 (Breast cancer) NCT00113841 (Multiple Myeloma) |
Sulforaphane | EZH2 | Melanoma | 100 | NCT01228084 (Prostate cancer) NCT00946309 (Prostate cancer) NCT00894712 (Breast cancer) NCT00982319 (Breast cancer) |
Tanshindiols | EZH2 | B cell lymphoma | 101 | No studies |
Rottlerin | EZH2 | Prostate cancer | 102 | No studies |
Olive oil | HDAC | Multiple Myeloma | 103 | NCT02599103 (Colorectal Neoplasms) |
Ibotenic acid | HDAC7 | Breast cancer | 104 | No studies |
Baicalein | HDAC | Core binding factor-acute myeloid leukemia | 105 | No studies |